1.1Branched chain at R1
The isopropyl group attaches through its methine carbon and places two methyl groups next to the attachment point. Its branching concentrates nonpolar surface near the scaffold without closing a ring.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The isopropyl group attaches through its methine carbon and places two methyl groups next to the attachment point. Its branching concentrates nonpolar surface near the scaffold without closing a ring.
A pyridin-3-yl group attaches through carbon 3 and presents a planar six-membered aromatic ring. The ring nitrogen at position 1 supplies a hydrogen-bond acceptor.
The scaffold bonds directly to sulfur in the –S(=O)₂CH₃ group. The two sulfonyl oxygens accept hydrogen bonds and give the substituent a strong dipole.
The –C(=O)NHCH₃ group attaches through its carbonyl carbon. Its carbonyl oxygen accepts a hydrogen bond, and its N–H group donates one.
The –CH₂CH₂OCH₃ chain places an ether oxygen two carbons from the scaffold. The oxygen accepts a hydrogen bond, and rotation about the chain bonds changes its orientation.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An analytical laboratory uses a purified spirocyclic heterocyclic derivative as a retention time and detector response reference. The laboratory prepares a concentration series by diluting a weighed stock solution with a solvent compatible with the liquid chromatography method. It injects the series alongside solvent blanks and compares retention times and peak areas across runs.
A benzene ring occupies position A and carries a methanesulfonamido group at R3 in place of an amino group. The R3′ position carries hydrogen. Methanesulfonyl chloride reacts with the corresponding ring-bound primary amine in the presence of a tertiary amine base to form the nitrogen–sulfur bond.
A matched series fixes R1 as methyl, A as benzene, and both R3 and R3′ as hydrogen. R2 takes four linear alkyl forms containing 1, 2, 4, or 6 carbon atoms. A shake-flask assay equilibrates each derivative in the same aqueous buffer at 25 °C for 24 hours and quantifies the dissolved fraction by liquid chromatography.
A 24-well plate holds 12 duplicate conditions for a derivative with a protonatable tertiary amine. The conditions combine hydrochloric, fumaric, or citric acid with two solvent compositions and acid-to-amine molar ratios of 0.5 or 1.0. Each well receives 2 mg of the derivative, and controlled evaporation yields residues for powder X-ray diffraction. Proton nuclear magnetic resonance spectroscopy or ion chromatography measures counterion content in samples with distinct diffraction patterns.
A capsule contains a spray-dried dispersion of a selected derivative in polyvinylpyrrolidone. The derivative and polymer dissolve in a common volatile solvent, and a spray dryer removes the solvent from atomized droplets. The dried powder is blended with microcrystalline cellulose and filled into capsules, and the polymer disperses as the capsule contents hydrate.
A structure enumeration program attaches selected R1, R2, A, R3, and R3′ fragments to a digital template at labeled attachment points. The program checks atomic valence, preserves specified stereochemistry, and removes duplicate structures using canonical representations. It ranks the resulting structures using measured solubility and permeability from related derivatives as training data. The output records each candidate structure, its predicted properties, and the model uncertainty.
R1 is a 3,3-difluorocyclobutyl group that attaches through carbon 1 of the four-membered ring. Both fluorine atoms occupy carbon 3.
A is a five-membered aromatic oxazole ring with oxygen at position 1 and nitrogen at position 3. The ring attaches to the scaffold through carbon 4.
R3 is a 4-(4-fluorophenoxy)piperidin-1-yl group, with the piperidine nitrogen bonded to A. The phenoxy oxygen links carbon 4 of piperidine to a phenyl ring that carries fluorine para to the oxygen.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
A compound according to formula I: or a pharmaceutically acceptable salt thereof wherein the C5-C6 bond can either be saturated or unsaturated; R1 is phenyl or (2-5C)heteroaryl, both optionally substituted with one or more substituents selected from R13 or R1 is (1-6C)alkyl, halogen, cyano, (2-6C)alkenyl, (2-6C)alkynyl, (3-6C)cycloalkyl, (5-6C)cycloalkenyl, (2-5C)heterocycloalkyl or (2-5C)-heterocycloalkenyl;A · US 8,071,587 B2 · claim 1
A compound of the formula I: or a pharmaceutically acceptable salt thereof, wherein: X is R is H, or C1-6alkyl, wherein alkyl substituents are further optionally substituted with 1-4 halogen substituents, R′ is H, or C1-6alkyl, wherein alkyl substituents are further optionally substituted with 1-4 halogen substituents, R1 is OH, H, CH2OH, or C1-6alkylOC1-6alkyl, wherein alkyl substituents are further optionally substituted with 1-4 halogen substituents, or X and R1 together fB · US 2016/0324833 A1 · claim 1
An empty cell means only that no passage was reproduced there.
Low molecular weight FSHR agonists can be used for the same clinical purposes as native FSH, i.e. for the treatment of infertility and for controlled ovarian stimulation preceeding in vitro fertilisation.A · US 8,071,587 B2 · ¶ 5
There clearly is a need for low molecular weight hormone mimetics that selectively activate the FSH receptor.A · US 8,071,587 B2 · ¶ 8
Selective inhibitors of the ROMK channel (also referred to herein as inhibitors of ROMK or ROMK inhibitors) are expected to represent novel diuretics for the treatment of hypertension and other conditions where treatment with a diuretic would be beneficial with potentially reduced liabilities (i.e., hypo- or hyperkalemia, new onset of diabetes, dyslipidemia) over the currently used clinical agents (see Lifton, R.B · US 2016/0324833 A1 · ¶ 2
The continued discovery of selective small molecule inhibitors of ROMK is needed for the development of new treatments for hypertension, heart failure, edematous states and related disorders.B · US 2016/0324833 A1 · ¶ 4
patent.fyi, US 2026/0356827 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356827/, SHA-256 be1d52238b21a132b6162db9059ba2e519c7594770b863f2c89615f02b07ce79